AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Over the past few years, API security has gone from a relatively niche concern to a headline issue. A slew of high-profile breaches and compliance mandates like PCI DSS 4.0 have woken security teams ...

For brands to thrive in today's ever-changing landscape, they must cultivate a deep understanding of their purpose. This ...

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...